Gang Chen
Hematology & Oncology · Towson, MDNPI 1417390576
Payments from drug & device makers
Across 164 payments — averaging $117.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$14K
- E.r. Squibb & Sons, L.L.C.$2K
- Daiichi Sankyo Inc.$375
- Johnson & Johnson$274
- Gilead$243
- Exelixis Inc.$231
- plus $2K from 35 others
What the payments were for
- Consulting fees$4,32550%
- Food & beverage$4,27649%
- Education$1101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $13,653 |
| E.r. Squibb & Sons, L.L.C. | 14 | $2,209 |
| Daiichi Sankyo Inc. | 15 | $375 |
| Johnson & Johnson(2 entities) | 11 | $274 |
| Gilead | 6 | $243 |
| Exelixis Inc. | 5 | $231 |
| Incyte Corporation | 9 | $227 |
| Regeneron Healthcare Solutions, Inc. | 7 | $191 |
| Novartis | 8 | $188 |
| Bristol Myers Squibb | 6 | $155 |
| Merck | 7 | $143 |
| Eisai Inc. | 3 | $141 |
| Stemline Therapeutics Inc. | 1 | $131 |
| AbbVie | 5 | $125 |
| Pfizer | 5 | $100 |
| Lilly USA, LLC | 4 | $95 |
| AVEO Pharmaceuticals, Inc. | 1 | $85 |
| Bayer | 2 | $63 |
| GSK | 3 | $61 |
| Taiho Oncology, Inc. | 2 | $58 |
| Beone Medicines USA, Inc. | 2 | $53 |
| Sanofi | 2 | $53 |
| Array Biopharma Inc | 2 | $49 |
| Genentech USA, Inc. | 2 | $42 |
| Seagen Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $29 |
| Geron Corporation | 1 | $29 |
| Pharmacosmos Therapeutics Inc. | 1 | $27 |
| Tolmar, Inc. | 1 | $27 |
| Pharmaand GmbH | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| GE HealthCare | 1 | $26 |
| Deciphera Pharmaceuticals Inc. | 1 | $25 |
| Morphosys, US Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,340 in reported general payments places this provider in the 55th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 19 | $421,485 |
| ImbruvicaIbrutinib | 23 | $376,158 |
| Lenalidomide | 26 | $367,056 |
| SprycelDasatinib | 13 | $236,817 |
| RevlimidLenalidomide | 13 | $232,264 |
| BrukinsaZanubrutinib | 13 | $121,727 |
| EliquisApixaban | 122 | $82,948 |
| XareltoRivaroxaban | 76 | $74,202 |
| Imatinib Mesylate | 67 | $72,357 |
| CreonLipase/Protease/Amylase | 31 | $16,781 |
| Anastrozole | 48 | $1,194 |
| Prochlorperazine Maleate | 95 | $936 |
| Hydroxyurea | 42 | $889 |
| Letrozole | 26 | $799 |
| Acyclovir | 29 | $646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $2,209 | $658,30232 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $19 | $376,15823 claims |
| Bristol Myers SquibbRevlimid | $155 | $232,26413 claims |
| PfizerEliquis | $100 | $82,948122 claims |
| Johnson & JohnsonXarelto | $274 | $74,20276 claims |
| AbbVieCreon | $125 | $16,78131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Towson
- Robert KreitmanOlney$54.2M
- Ralph BocciaBethesda$12.1M
- Dan ZandbergBaltimore$9.9M
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Giuseppe GiacconeBethesda$5.4M
- Ivana GojoBaltimore$5M
- Suman RaoBaltimore$4.2M
- Tim GretenBethesda$4.2M
- Patrick FordeBaltimore$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.